All In Biotech

Drug Trial Radar · NCT00003569

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol

Last checked: Nov 19, 2026Latest source record: Jan 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2

Actual

Start

Mar 1998

Primary completion

Jun 2003

Sponsor

Lead sponsor
Roswell Park Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating patients with solid tumors who are receiving cisplatin and paclitaxel.

Conditions

  • Head and Neck Cancer
  • Lung Cancer
  • Neurotoxicity
  • Ovarian Cancer

Interventions

  • cisplatinDrug

  • dimesnaDrug

  • paclitaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Chicago Cancer Research Center

    Chicago, Illinois

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Roswell Park Cancer Institute

    Buffalo, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.